Xtandi 40 mg Capsule
PDF Leaflet Revision Date: 29 February 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of metastatic hormone-sensitive and castration-resistant prostate cancer in adult men.
Dosage (summary)
160 mg once daily; reduce to 120 mg or 80 mg if toxicity occurs.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in women; may impair male fertility.
Key Drug Interactions
- Strong CYP2C8 inhibitors
- Warfarin
- CYP3A4 inhibitors
Contraindications
- Hypersensitivity
- Uncontrolled seizures
- Not for use in women
Common side effects
- Fatigue
- Hot flushes
- Hypertension
- Fractures
- Cognitive disorder
Counselling Points
- Take capsules whole with water
- Use contraception during and for 3 months after treatment
- Monitor for signs of gastrointestinal bleeding
Serious warnings
- Risk of seizure
- Posterior reversible encephalopathy syndrome
- Second primary malignancies
Important Disclaimer
The Xtandi 40 mg Capsule professional information leaflet below is the property of Astellas Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
